contrast
rel
ubiquit
angiotensinconvert
enzym
ace
express
mammalian
ace
homologu
initi
describ
heart
kidney
testi
type
integr
membran
protein
activ
site
domain
expos
extracellular
surfac
endotheli
cell
renal
tubular
epithelium
pois
metabolis
circul
peptid
may
includ
angiotensin
ii
potent
vasoconstrictor
product
angiotensin
cleavag
ace
end
may
counterbal
effect
ace
within
reninangiotensin
system
ra
inde
implic
regul
heart
renal
function
propos
control
level
angiotensin
ii
rel
hypotens
metabolit
angiotensin
recent
solut
structur
ace
provid
new
insight
substrat
inhibitor
profil
two
key
regul
ra
complex
crucial
pathway
unravel
grow
interest
therapeut
potenti
agent
modul
activ
cell
surfac
particularli
cell
type
endow
proteolyt
activ
abl
modul
activ
membran
protein
circul
regulatori
peptid
proteas
peptidas
mostli
metalloenzym
use
zinc
cofactor
structur
organis
ectoenzym
catalyt
site
face
extracellular
space
exampl
includ
neutral
endopeptidas
neprilysin
nep
aminopeptidas
carboxypeptidas
variou
specif
subject
articl
angiotensinconvert
enzym
ace
ectopeptidas
mainli
exist
singl
membranespan
protein
type
cterminu
intracellular
type
ii
nterminu
intracellular
topolog
glycosylphosphatidylinositollink
protein
undoubtedli
best
studi
ectopeptidas
far
ace
larg
physiolog
patholog
role
almost
year
ace
uniqu
mammalian
enzym
distinct
grow
peptidas
famili
discoveri
human
homologu
ace
aceh
led
resurg
studi
ace
biolog
coupl
detail
structur
inform
enzym
pace
knowledg
concern
breathtak
comparison
rel
leisur
develop
understand
ace
structur
function
sever
decad
period
year
clone
purifi
knockedout
knockedin
inhibitor
develop
structur
determin
new
function
emerg
implic
cardiovascular
renal
biolog
diabet
obes
remark
may
serv
receptor
sever
acut
respiratori
syndrom
sar
viru
cardiovascular
diseas
continu
one
lead
caus
death
develop
countri
commonli
result
hypertens
congest
heart
failur
major
revolut
treatment
hypertens
came
develop
inhibitor
ace
ace
inhibitor
eg
captopril
lisinopril
prove
highli
effect
safe
drug
use
clinic
treat
hypertens
also
congest
heart
failur
renal
disord
inhibit
ace
impos
effect
primarili
via
ra
ra
mediat
numer
effect
cardiovascular
system
includ
blood
pressur
homeostasi
mainten
fluid
salt
balanc
ace
crucial
regul
ra
convert
inact
decapeptid
angiotensin
potent
vasoconstrictor
angiotensin
ii
whilst
also
metabolis
hypotens
peptid
bradykinin
novel
mammalian
homologu
ace
origin
term
aceh
subsequ
identifi
two
distinct
molecular
strategi
gene
map
human
x
chromosom
encod
type
membranebound
glycoprotein
appar
molecular
weight
approxim
kda
aminotermin
domain
share
around
sequenc
ident
correspond
domain
somat
ace
contain
singl
hexxh
zincbind
motif
intriguingli
carboxytermin
domain
display
sequenc
homolog
collectrin
enzym
inact
glycoprotein
unknown
function
express
exclus
kidney
initi
appear
limit
tissu
distribut
ace
signific
level
detect
heart
kidney
test
gastrointestin
tract
recent
studi
howev
detect
signific
level
express
wide
varieti
tissu
first
inspect
owe
high
degre
sequenc
similar
exist
ace
could
assum
might
function
like
ace
dipeptidyl
carboxypeptidas
inde
previous
characteris
acelik
protein
drosophila
ace
orthologu
anc
acer
display
activ
surprisingli
howev
function
carboxypeptidas
cleav
singl
ctermin
residu
peptid
substrat
tabl
inde
unabl
cleav
archetyp
ace
substrat
bradykinin
hiphisleu
insensit
potent
ace
inhibitor
lisinopril
captopril
characteris
use
panel
biolog
activ
peptid
provid
consensu
sequenc
proxprohydrophobicbas
proteas
specif
consensu
sequenc
support
activ
site
model
propos
guy
et
al
also
ascertain
chain
length
hydrolys
peptid
limit
although
cleavag
dipeptid
slow
catalyt
activ
like
ace
phand
aniondepend
structur
tace
drosophila
homologu
anc
recent
elucid
minimum
glycosyl
requir
express
process
enzym
activ
tace
investig
progress
deglycosyl
truncat
solubl
form
tace
lack
first
residu
nterminu
express
cho
cell
presenc
glycosidasei
inhibitor
nbutyldeoxynojirimycin
retain
activ
nativ
enzym
yield
crystal
diffract
resolut
natesh
et
al
describ
structur
tace
alon
complex
inhibitor
lisinopril
therebi
provid
detail
pictur
activ
site
tace
molecul
overal
ellipsoid
shape
central
groov
extend
approxim
protein
divid
two
subdomain
activ
site
locat
toward
bottom
groov
simultan
crystal
structur
drosophila
anc
determin
clear
inform
present
minim
glycosyl
form
anc
express
purifi
crystallis
studi
howev
previou
report
separ
group
shown
anc
requir
glycosyl
secret
activ
data
anc
crystal
reveal
like
ace
larg
intern
channel
encompass
entir
protein
molecul
activ
site
locat
bottleneck
connect
two
chamber
unequ
size
within
caviti
recent
crystal
structur
extracellular
domain
lack
transmembran
cytosol
region
nativ
inhibitorbound
determin
resolut
respect
data
confirm
integr
activ
site
model
propos
guy
et
al
model
base
crystal
structur
tace
indic
catalyt
mechan
resembl
ace
predict
structur
differ
activ
site
ace
dipeptidyl
carboxypeptidas
carboxypeptidas
respons
differ
specif
also
verifi
structur
essenc
main
differ
occur
ligandbind
pocket
particularli
subsit
ace
bind
peptid
carboxyterminu
caviti
tace
larger
allow
extra
amino
acid
bind
specif
pocket
importantli
q
substitut
ace
appear
larg
respons
elimin
pocket
structur
differ
offer
explan
classic
ace
inhibitor
lisinopril
unabl
bind
crystal
grown
presenc
reveal
unanticip
invers
bind
orient
inhibitor
activ
site
fig
rationalis
v
substitut
ace
wherebi
size
pocket
consider
reduc
longer
accommod
bulki
dichlorobenzyl
group
moreov
explain
substrat
like
bradykinin
angiotensin
leuenkephalin
poor
substrat
good
substrat
ace
anoth
surpris
observ
absenc
bound
chlorid
ident
posit
second
bind
site
tace
occupi
site
larg
respons
chlorid
activ
ace
clearli
differ
ace
display
uniqu
enzym
function
despit
sequenc
similar
exist
two
protein
common
featur
activ
profil
first
class
select
inhibitor
includ
seri
nonpeptid
compound
whose
design
base
upon
substrat
specif
requir
central
locat
carboxyl
coordin
inhibitor
lead
compound
possess
subnanomolar
affin
ic
nm
less
affin
human
tace
bovin
carboxypeptidasea
cpa
respect
use
altern
strategi
potent
peptid
inhibitor
identifi
screen
constrain
peptid
librari
stabl
peptid
inhibitor
display
k
nm
angiotensin
substrat
ntermin
acetyl
ctermin
amid
peptid
addit
dipeptid
proph
identifi
inhibitor
activ
find
would
allow
peptidebas
approach
inhibitor
design
comparison
inhibitori
effect
proph
proleu
substrat
weaker
inhibitor
proph
dipeptid
inhibitor
compound
fundament
tool
explor
biolog
enzymolog
comparison
way
first
inhibitor
ace
discov
quit
differ
teprotid
nonapeptid
owe
potenc
select
natur
select
compon
venom
brazilian
pitvip
captopril
hand
owe
potenc
select
chemic
design
guid
hypothet
activ
site
model
also
data
substrat
specif
ace
comparison
cpa
exampl
studi
carri
cheung
et
al
major
contribut
factor
design
secondgener
inhibitor
ace
activ
site
bind
properti
substrat
competit
inhibitor
ace
investig
use
seri
simpl
triand
dipeptid
determin
bind
substrat
inhibitor
ace
wholli
depend
upon
ctermin
residu
subsit
interact
vein
import
exhaust
studi
determin
structureact
correl
critic
systemat
develop
inhibitor
compound
although
ace
inhibitor
design
part
basi
similar
enzym
properti
ace
cpa
signific
segment
homolog
found
carboxypeptidas
famili
upon
solut
crystal
structur
tace
contrast
grow
avail
data
enzym
kinet
possibl
physiolog
role
compar
littl
known
cellular
level
keep
predict
made
peptid
sequenc
interact
viral
receptor
recombin
express
cho
cell
localis
predominantli
plasma
membran
analysi
media
taken
cell
express
reveal
presenc
solubl
form
like
product
proteolyt
cleavag
event
inde
proteolyt
releas
observ
cardiomyocyt
overexpress
solubl
form
detect
urin
dw
lambert
gi
rice
nm
hooper
aj
turner
unpublish
data
preliminari
evid
indic
secretas
respons
shed
distinct
ace
dw
lambert
nm
hooper
aj
turner
unpublish
data
light
abil
solubl
prevent
sar
cov
infect
studi
secret
prime
signific
analysi
sequenc
reveal
presenc
seven
potenti
nglycosyl
sequon
recent
resolv
crystal
structur
provid
evid
six
site
glycosyl
clear
data
whether
ctermin
site
also
occupi
studi
report
solubl
express
insect
cell
molecular
weight
kda
compar
predict
kda
differ
account
presenc
carbohydr
group
molecular
weight
kda
also
report
rat
mous
tissu
note
howev
studi
report
molecular
weight
kda
speci
inde
overexpress
mammalian
cell
appar
molecular
weight
kda
reduc
approxim
kda
follow
enzym
deglycosyl
whilst
differ
report
molecular
weight
insect
mammalian
cell
assign
speci
differ
posttransl
modif
reason
remain
discrep
unclear
disrupt
normal
glycosyl
express
cho
cell
treatment
glycosidas
inhibitor
tunicamycin
prevent
correct
cellular
sort
fulllength
abolish
secret
truncat
mutant
lack
transmembran
cytosol
domain
dw
lambert
k
pogson
aj
turner
unpublish
observ
result
unglycosyl
protein
also
catalyt
inact
indic
requir
glycosyl
membran
target
activ
vivo
express
confin
endotheli
cell
renal
tubular
epithelium
also
identifi
vascular
smooth
muscl
cell
leydig
sertoli
cell
test
first
direct
evid
concern
physiolog
role
provid
studi
transgen
knockout
mice
carri
crackow
et
al
mice
show
gross
abnorm
fertil
normal
blood
pressur
renal
function
despit
moder
elev
angiotensin
ii
level
closer
examin
howev
reveal
mice
suffer
sever
cardiac
dysfunct
manifest
profound
decreas
cardiac
contractil
result
thin
left
ventricl
wall
increas
ventricl
chamber
dimens
disrupt
heart
function
associ
upregul
gene
induc
hypoxia
bore
remark
resembl
condit
result
cardiac
surgeri
refer
dcardiac
stunningt
significantli
ablat
ace
gene
knockout
background
rescu
cardiac
phenotyp
suggest
serv
regul
effect
ace
ra
separ
studi
target
disrupt
gene
result
viabl
fertil
progeni
lack
gross
anatomicalstructur
abnorm
display
moder
elev
systol
blood
pressur
chronic
infus
angiotensin
ii
level
induc
hypertens
increas
blood
pressur
decreas
heart
rate
evid
null
mice
compar
wildtyp
litterm
thu
appear
absenc
mice
suscept
angiotensin
iiinduc
hypertens
transgen
mice
overexpress
exclus
cardiac
myocyt
exhibit
complet
atrioventricular
block
week
age
transgen
mice
appear
healthi
grossli
normal
heart
structur
slightli
lower
blood
pressur
howev
mice
suffer
increas
suscept
sudden
cardiac
death
directli
correl
transgen
dose
detail
electrophysiolog
analysi
reveal
sever
progress
conduct
rhythm
disturb
along
sustain
ventricular
tachycardia
termin
ventricular
fibril
light
observ
gap
junction
protein
downregul
heart
transgen
mice
suggest
electr
remodel
result
gap
junction
dysregul
surviv
older
mice
express
human
cardiac
myocyt
progress
downregul
downregul
protein
control
heartspecif
amhc
promot
phenomenon
report
model
coincid
reciproc
upregul
result
partial
restor
cardiac
phenotyp
howev
import
note
normal
express
cardiac
myocyt
rather
cardiac
endothelium
abil
cleav
vasoact
peptid
angiotensin
ii
indic
possibl
role
blood
pressur
regul
theori
given
increas
credenc
observ
gene
map
candid
quantit
trait
locu
qtl
saltsensit
rat
model
hypertens
furthermor
rat
display
reduc
mrna
protein
express
compar
healthi
litterm
overlap
qtl
also
identifi
rat
model
hypertens
addit
two
singl
nucleotid
polymorph
snp
identifi
locu
associ
risk
cardiovascular
diseas
caucasian
popul
chronic
administr
omapatrilat
dual
inhibitor
vasopeptidas
ace
neprilysin
nep
spontan
hypertens
rat
shr
result
signific
reduct
blood
pressur
mark
diuresi
augment
renal
excret
vasodilatori
peptid
angiotensin
capabl
produc
angiotensin
angiotensin
ii
vitro
abundantli
express
kidney
upon
treatment
shr
omapatrilat
increas
stain
angiotensin
observ
renal
proxim
tubul
simultan
increas
mrna
express
cortex
author
suggest
omapatrilat
exert
effect
induc
express
result
concomit
increas
angiotensin
product
angiotensin
ii
associ
decreas
blood
pressur
rather
via
inhibit
ace
nep
known
cleav
angiotensin
demonstr
concentr
angiotensin
kidney
urin
increas
normal
pregnanc
rat
light
evid
renal
express
brosnihan
et
al
investig
possibl
chang
express
may
associ
previou
find
level
angiotensin
increas
pregnanc
found
renal
distribut
angiotensin
similar
chang
gestat
howev
intens
stain
elev
respect
pregnant
rat
find
suggest
primari
candid
local
product
increas
angiotensin
gener
pregnanc
evid
role
may
play
ra
came
studi
zisman
et
al
report
upregul
express
fail
human
heart
ventricl
parallel
paper
group
present
evid
involv
novel
angiotensin
activ
intact
fail
heart
later
studi
demonstr
format
angiotensin
correl
level
express
could
complet
abolish
administr
inhibitor
data
indic
fail
heart
major
rout
increas
product
angiotensin
angiotensin
ii
via
rather
angiotensin
via
neprilysin
previous
suggest
separ
studi
implic
renal
pathogenesi
diabet
nephropathi
studi
shown
mrna
protein
express
level
significantli
reduc
kidney
streptozocininduc
diabet
rat
reduct
mrna
express
influenc
ace
inhibitor
treatment
howev
decreas
protein
express
prevent
condit
therebi
suggest
protein
express
associ
ace
activ
contrast
renal
protein
found
higher
absenc
concomit
increas
mrna
level
young
diabet
mice
dbdb
onset
diabet
nephropathi
balanc
ace
low
versu
high
protein
level
respect
may
renoprotect
earli
stage
diabet
balanc
lost
upon
progress
renal
damag
henc
postul
involv
aetiolog
diabet
via
ra
role
previous
characteris
diseas
state
review
see
ref
collect
studi
vivo
provid
strong
evid
role
ra
localis
product
angiotensin
angiotensin
ii
perhap
serv
neg
regul
vasoconstrict
effect
ace
maintain
blood
pressur
homeostasi
maintain
cardiac
renal
function
fig
surpris
discoveri
function
receptor
sar
coronaviru
caus
agent
sar
seri
eleg
experi
li
et
al
coimmunoprecipit
viru
attach
glycoprotein
lysat
african
green
monkey
kidney
cell
line
vero
subject
precipit
protein
mass
spectrometri
among
sequenc
number
obtain
correspond
subsequ
demonstr
recombin
solubl
ace
abl
block
associ
vero
cell
sar
cov
protein
express
recombin
protein
result
cell
fusion
format
syncytia
cell
cell
line
normal
resist
sar
cov
infect
furthermor
cell
express
permit
effici
replic
coronaviru
viral
genom
copi
increas
period
compar
untransfect
cell
antibodi
inhibit
cytopath
sarscov
dosedepend
manner
express
profil
mrna
perform
harmer
et
al
demonstr
express
low
level
bronchu
lung
parenchyma
taken
togeth
evid
primari
site
murin
express
lung
kidney
led
li
et
al
suggest
tissu
distribut
consist
patholog
sarscov
furthermor
ham
et
al
recent
provid
evid
abundantli
express
epithelia
lung
small
intestin
possibl
entri
site
sar
viru
whilst
research
determin
receptor
bind
properti
sar
cov
protein
progress
rapid
rate
littl
known
residu
involv
bind
preliminari
experi
perform
li
et
al
indic
disrupt
activ
site
effect
bind
studi
requir
understand
natur
protein
protein
interact
recent
wide
assum
intricaci
ra
larg
elucid
recent
studi
examin
properti
howev
provid
evid
crucial
pathway
may
significantli
complic
previous
thought
whilst
yet
precis
physiolog
role
remain
determin
becom
increasingli
appar
may
act
counterbal
effect
ace
ra
given
signific
ace
inhibitor
treatment
number
pathophysiolog
disord
contribut
regul
ra
ignor
inde
modul
activ
may
provid
signific
new
therapeut
opportun
treatment
cardiovascular
diseas
either
isol
conjunct
exist
ace
inhibitor
excit
possibl
highlight
need
continu
effort
elucid
vivo
role
biochem
properti
emerg
player
ra
fig
schemat
represent
reninangiotensin
system
ra
ace
angiotensinconvert
enzym
nep
neprilysin
angiotensin
ii
type
receptor
angiotensin
type
ii
receptor
convers
angiotensin
angiotensin
kinet
much
less
favour
convers
angiotensin
ii
angiotensin
